Center of Excellence for Antibody Research
CEAR – special focus
The Center of Excellence for Antibody Research (CEAR), was founded at FTM in 2009. The goal of the Center is to produce therapeutic products against infectious diseases. The Center currently employs 6 full-time staffs. It is equipped with state-of-the-art facilities, including apparatus necessary for flow cytometry, viral culture and real-time PCR.
JICA Scientific Meeting
On 10 August 2022, Center of Excellence for Antibody Research (CEAR), Faculty of Tropical Medicine, Mahidol University together with Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health of Thailand and Department of Medical Sciences, Ministry of Public Health of Thailand hosted the JICA Scientific Meeting for Research on SARS-CoV-2 response to effective detection, discovery and production of Biotherapeutic against SAR-CoV-2 and other viral pathogens. This meeting was also supported by Japan International Cooperation Agency (JICA) in collaboration with Research Institute for Microbial Diseases, Osaka University (RIMD, OU), International Center for Biotechnology, Osaka University (ICB, OU), Faculty of Pharmaceutical Sciences, Chulalongkorn University and Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang.
To promote and increase the discovery research at faculty of Tropical Medicine, Mahidol University (FTM-MU) the brand-new Center of Excellence for Antibody Research (CEAR), was launched in late 2009. Simultaneously, CEAR, FTM-MU and Research Institute of Microbial Diseases (RIMD), Osaka University (OU), have started the research collaboration project “Research and Development of Therapeutic Products against Infectious Diseases, Especially Dengue virus Infection” and set up “MAHIDOL-JST-JICA friendship Laboratory” with partial support of 46 million baht (equipment, and reagents), from the Japanese government, by 4 years (2009-2012) contracted under the “Science and Technology Research Partnership for Sustainable Development, promoted by Japan International Cooperation Agency (JICA), and also technical support by experts from RIMD, OU.
Until present (May, 2011), 11 human monoclonal antibodies (MAbs) clones that can neutralize 4 serotypes of Dengue virus have been developed, which are waiting for patent application. These 11 MAbs are candidate for Dengue treatment in the future. Moreover, various new MAbs that can be used in the diagnosis of tropical diseases, such as influenza virus, leptospirosis, Aeromonas, and foot-and-mouth-disease virus infections, have been developed using classical hybridoma and novel phage-display technologies.
A rapid-test kit that can be used to detect and differentiate H5N1 influenza virus from other influenza viruses, is now in production at the licensed company. A new human MAb that can be used to treat H5N1 Influenza virus has been developed, and human MAb specific to Dengue, and HIV viruses, are under development, using novel human hybridoma (SPYMEG cell) technology.
CEAR provides services and assistance to other departments at FTM. They work closely with the Hospital for Tropical Diseases, and are able to provide dengue virus diagnosis via PCR. In addition to this, the Center can provide services to FTM staff, such as flow cytometry, protein interaction array analysis, and real-time PCR.